/Dexcom%20Inc%20HQ-by%20JHVEPhoto%20via%20Shutterstock.jpg)
San Diego, California-based DexCom, Inc. (DXCM) is a medical device company that designs, develops, and commercializes continuous glucose monitoring (CGM) systems. Valued at $24.8 billion by market cap, the company develops a small implantable device that continuously measures glucose levels in subcutaneous tissue just under the skin and a small external receiver to which the sensor transmits glucose levels at specified intervals.
Companies worth $10 billion or more are generally described as “large-cap stocks,” and DXCM perfectly fits that description, with its market cap exceeding this mark, underscoring its size, influence, and dominance within the medical devices industry. DexCom leads in diabetes care with its advanced CGM systems like G6 and G7, driving innovation and convenience. Strategic partnerships with insulin pump companies enhance its offerings and market reach, solidifying its position in the growing diabetes market.